Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.

被引：2
|
作者：
Piha-Paul, Sarina Anne
Fu, Siqing
Hong, David S.
Janku, Filip
Karp, Daniel D.
Naing, Aung
Pant, Shubham
Ahnert, Jordi Rodon
Subbiah, Vivek
Tsimberidou, Apostolia Maria
Yap, Timothy Anthony
Meric-Bernstam, Funda
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
[3] Vall Hebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2611
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2611
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
    Sarina A. Piha-Paul
    Chieh Tseng
    Hai T. Tran
    Meng Gao
    Daniel D. Karp
    Vivek Subbiah
    Apostolia Maria Tsimberidou
    Jitesh D. Kawedia
    Siqing Fu
    Shubham Pant
    Timothy A. Yap
    Van K. Morris
    Bryan K. Kee
    Mariela Blum Murphy
    JoAnn Lim
    Funda Meric-Bernstam
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 107 - 118
  • [2] A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
    Piha-Paul, Sarina A.
    Tseng, Chieh
    Tran, Hai T.
    Gao, Meng
    Karp, Daniel D.
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Kawedia, Jitesh D.
    Fu, Siqing
    Pant, Shubham
    Yap, Timothy A.
    Morris, Van K.
    Kee, Bryan K.
    Blum Murphy, Mariela
    Lim, JoAnn
    Meric-Bernstam, Funda
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (02) : 107 - 118
  • [3] HER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib
    Tomasevic, Z.
    Smyth, L. M.
    Saura, C.
    Boni, V.
    Garcia-Saenz, J. A.
    Prat, A.
    Eli, L.
    Garza, S. J.
    Lalani, A. S.
    Crown, J. P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] EGFR and HER2 mutation and gene amplification in non-small-cell lung cancer
    Toshihiko, Yokoyama
    Kondo, Masashi
    Goto, Yasuhiro
    Fukui, Takayuki
    Yoshioka, Hiromu
    Yokoi, Kohei
    Kondo, Yutaka
    Osada, Hirotaka
    Imaizumi, Kazuyoshi
    Hasegawa, Yoshinori
    Shimokata, Kaoru
    Sekido, Yoshitaka
    CANCER RESEARCH, 2006, 66 (08)
  • [5] An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
    Decoster, Lore
    Cappoen, Nadia
    Aftimos, Philippe Georges
    Raicevic, Gordana
    Rolfo, Christian Diego
    Rottey, Sylvie
    Duhoux, Francois P.
    Collignon, Joelle
    Hebrant, Aline
    Vandenbulcke, Marc
    De Greve, Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Afatinib in Advanced Lung Squamous Cancer Harboring HER2 Mutation in Exon 17 Plus Amplification
    Wang, Yu-Ji
    Zeng, Da-Xiong
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (05) : e594 - e596
  • [7] Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient
    Bidard, Francois-Clement
    Ng, Ck
    Tulukcuoglu, Ezgi
    Piscuoglio, S.
    Descroix, Stephanie
    Mignot, Laurent
    Viovy, Jean-Louis
    Cottu, Paul
    Sigal, Brigitte
    Vincent-Salomon, Anne
    Weigelt, Britta
    Pierga, Jean-Yves
    Reis-Filho, Jorge
    CANCER RESEARCH, 2015, 75
  • [8] A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
    Thavaneswaran, Subotheni
    Lin, Frank
    Grady, John P.
    Espinoza, David
    Huang, Min Li
    Chinchen, Sarah
    Sebastian, Lucille
    Kansara, Maya
    Mersiades, Tony
    Lee, Chee Khoon
    Desai, Jayesh
    Grimison, Peter
    Brown, Michael
    Millward, Michael
    Harrup, Rosemary
    O'Byrne, Ken
    Nagrial, Adnan
    Craft, Paul
    Simes, John
    Joshua, Anthony M.
    Thomas, David M.
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [9] A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
    Zhou, C.
    Li, X.
    Yu, Q.
    Ning, R.
    Sun, M.
    Wang, Q.
    Liu, A.
    Tang, H.
    Tian, X.
    Zhou, Y.
    Wei, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S825 - S825
  • [10] Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer
    Kurata, Takayasu
    Tsurutani, Junji
    Fujisaka, Yasuhito
    Okamoto, Wataru
    Hayashi, Hidetoshi
    Kawakami, Hisato
    Shin, Eisei
    Hayashi, Nobuya
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (05) : 946 - 954
12345